Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China (Q42920406)

11 November 2017

Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China (English)

1 reference

People's Republic of China

11 November 2017

0 references

praziquantel

1 reference

inferred from title

Schistosoma japonicum

object named as

Schistosoma japonicum

1 reference

5

You-Sheng Liang

1 reference

11 November 2017

2

Jian-Rong Dai

1 reference

11 November 2017

Wei Wang

1

1 reference

PubMed ID

20810006

11 November 2017

Hong-Jun Li

series ordinal

3

1 reference

PubMed ID

20810006

11 November 2017

Xue-Hui Shen

series ordinal

4

1 reference

11 November 2017

1 November 2010

1 reference

11 November 2017

1 reference

11 November 2017

137

1 reference

11 November 2017

13

1 reference

11 November 2017

1905-1912

1 reference

A strategy to control transmission of Schistosoma japonicum in China

11 November 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Schistosomiasis control: experiences and lessons from China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Synthesis and properties of Praziquantel, a novel broad spectrum anthelmintic with excellent activity against Schistosomes and Cestodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Schistosoma mansoni: chemotherapy of infections of different ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Attempts to induce resistance in mice to Schistosoma japonicum and Schistosoma mansoni by exposure to crude schistosome antigens plus cloned glutathione-S-transferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Conquering 'snail fever': schistosomiasis and its control in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Susceptibility of Schistosoma japonicum to praziquantel in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Effects of the praziquantel-based control of schistosomiasis japonica in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Detection of praziquantel resistance in schistosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Epidemiology of schistosomiasis in the People's Republic of China, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Efficacy of praziquantel against Schistosoma japonicum: field evaluation in an area with repeated chemotherapy compared with a newly identified endemic focus in Hunan, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

A multi-level analysis of risk factors for Schistosoma japonicum infection in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Praziquantel, a new broad-spectrum antischistosomal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Transmission of Schistosoma japonicum by humans and domestic animals in the Yangtze River valley, Anhui province, China

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Clinical use of praziquantel in China

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Evaluation of Kato-Katz examination method in three areas with low-level endemicity of schistosomiasis japonica in China: A Bayesian modeling approach

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Use of praziquantel against schistosomiasis: a review of current status.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

Routine Kato-Katz technique underestimates the prevalence of Schistosoma japonicum: a case study in an endemic area of the People's Republic of China

1 reference

https://api.crossref.org/works/10.1017%2FS0031182010001204

7 January 2021

10.1017/S0031182010001204

Identifiers

DOI

1 reference

11 November 2017

1 reference

PubMed ID

20810006